Citius Pharmaceuticals Inc vs Innovative Industrial Properties Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Innovative Industrial Properties Inc trades at $58.2 (market cap $1.67B). The key difference: Innovative Industrial Properties Inc is far larger — about 83.5× Citius Pharmaceuticals Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | IIPR | |
|---|---|---|
Market Cap | $20.01M | $1.67B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $64.67 |
52-Week Low | $0.48 | $44.58 |
Enterprise Value | $16.23M | $2.21B |
Dividend Yield | — | 13.18% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.
Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →